JP2019513706A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513706A5 JP2019513706A5 JP2018549568A JP2018549568A JP2019513706A5 JP 2019513706 A5 JP2019513706 A5 JP 2019513706A5 JP 2018549568 A JP2018549568 A JP 2018549568A JP 2018549568 A JP2018549568 A JP 2018549568A JP 2019513706 A5 JP2019513706 A5 JP 2019513706A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- pharmaceutical composition
- onapristone
- methyl
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 13
- -1 methyl onapristone Chemical compound 0.000 claims 11
- 229950011093 onapristone Drugs 0.000 claims 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
- 229960004679 doxorubicin Drugs 0.000 claims 4
- 102000003998 progesterone receptors Human genes 0.000 claims 3
- 108090000468 progesterone receptors Proteins 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 2
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 229940043275 anti-HER2 drug Drugs 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000005265 lung cell Anatomy 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 claims 2
- 210000005267 prostate cell Anatomy 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 190000008236 Carboplatin Chemical compound 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims 1
- 229960000853 abiraterone Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000004958 brain cell Anatomy 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000002254 contraceptive effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000005168 endometrial cell Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 210000004216 mammary stem cell Anatomy 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 210000004409 osteocyte Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 201000007954 uterine fibroid Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310944P | 2016-03-21 | 2016-03-21 | |
| US62/310,944 | 2016-03-21 | ||
| PCT/US2017/023256 WO2017165315A1 (en) | 2016-03-21 | 2017-03-20 | Onapristone metabolite compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513706A JP2019513706A (ja) | 2019-05-30 |
| JP2019513706A5 true JP2019513706A5 (enExample) | 2020-04-30 |
Family
ID=59848182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549568A Pending JP2019513706A (ja) | 2016-03-21 | 2017-03-20 | オナプリストン代謝物質組成物及び方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20170266204A1 (enExample) |
| JP (1) | JP2019513706A (enExample) |
| WO (1) | WO2017165315A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2017112748A (ru) | 2014-11-17 | 2018-12-19 | Арно Терапьютикс, Инк. | Композиции онапристона пролонгированного действия и способы |
| AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
| KR20180113988A (ko) | 2015-12-15 | 2018-10-17 | 컨텍스트 바이오파마 인코포레이티드 | 비정질 오나프리스톤 조성물 및 그 제조방법 |
| WO2018102369A1 (en) | 2016-11-30 | 2018-06-07 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3321826A1 (de) * | 1983-06-15 | 1984-12-20 | Schering AG, 1000 Berlin und 4709 Bergkamen | 13(alpha)-alkylgonane, deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE102006054535A1 (de) * | 2006-11-15 | 2008-05-21 | Bayer Schering Pharma Aktiengesellschaft | Progesteronrezeptorantagonisten |
| TW201002736A (en) * | 2008-04-28 | 2010-01-16 | Repros Therapeutics Inc | Compositions and methods for treating progesterone-dependent conditions |
| US20130029953A1 (en) * | 2011-07-28 | 2013-01-31 | Klaus Nickisch | Progesterone antagonists |
| US9193757B2 (en) * | 2013-03-12 | 2015-11-24 | Arno Therapeutics, Inc. | Onapristone polymorphic forms and methods of use |
| US9096641B2 (en) * | 2013-06-05 | 2015-08-04 | Evestra, Inc. | Imidazolyl progesterone antagonists |
-
2017
- 2017-03-20 JP JP2018549568A patent/JP2019513706A/ja active Pending
- 2017-03-20 WO PCT/US2017/023256 patent/WO2017165315A1/en not_active Ceased
- 2017-03-20 US US15/464,085 patent/US20170266204A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7394974B2 (ja) | 酢酸アビラテロンを含む医薬組成物、並びにその製造方法及び使用 | |
| JP2022180461A5 (enExample) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| JP2012521435A5 (enExample) | ||
| JP2009539769A5 (enExample) | ||
| JP2008530248A5 (enExample) | ||
| JP2010525050A5 (enExample) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2019513706A5 (enExample) | ||
| JP2018184465A5 (enExample) | ||
| JP2010501576A5 (enExample) | ||
| JP2017516802A5 (enExample) | ||
| JP2021509395A5 (enExample) | ||
| BR112012030641B1 (pt) | Usos e composições para terapia farmacêutica oral | |
| JP2015517523A5 (enExample) | ||
| JP2018138594A (ja) | オナプリストン多形体及び使用方法 | |
| JP2010538066A5 (enExample) | ||
| RU2014137128A (ru) | Способ лечения заболеваний кишечника с присутствием по меньшей мере одного воспалительного компонента | |
| MX2011011765A (es) | Combinacion antitumoral que comprende cabazitaxel y capecitabina. | |
| TWI341728B (en) | Combinations comprising epothilones and anti-metabolites | |
| JP2019513706A (ja) | オナプリストン代謝物質組成物及び方法 | |
| JP2010504307A5 (enExample) | ||
| CA2563058A1 (en) | Supportive treatment of liver disease | |
| JP7357386B2 (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤 |